Literature DB >> 2896500

Reduced cyclosporin accumulation in multidrug-resistant cells.

H Goldberg1, V Ling, P Y Wong, K Skorecki.   

Abstract

Cyclosporin accumulation was reduced by 50% or more in multidrug- resistant CHRC5 CHO cells with high levels of P-glycoprotein expression compared to drug sensitive AuxB1 CHO cells. This difference could be overcome by verapamil which is known to interact with P-glycoprotein and reverse multidrug resistance. The difference in cyclosporin accumulation between sensitive and resistant cells decreased with increasing cyclosporin concentrations suggesting that cyclosporine itself regulated its own accumulation through interaction with P-glycoprotein. Indeed, cyclosporin also reversed differences in vinblastine accumulation between resistant and sensitive cell lines. Since P-glycoprotein is highly expressed in the kidney which is also a target for cyclosporin toxicity, the effects of verapamil on cyclosporin accumulation were studied in two renal cell lines, rat mesangial cells and LLCPK1, cells. Verapamil increased cyclosporin accumulation by approximately 70%. These results suggest that cellular cyclosporine accumulation is regulated at least in part by its interaction with P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896500     DOI: 10.1016/s0006-291x(88)80073-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

Review 1.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

2.  Resveratrol and P-glycoprotein inhibitors enhance the anti-skin cancer effects of ursolic acid.

Authors:  Jacob J Junco; Anna Mancha; Gunjan Malik; Sung-Jen Wei; Dae Joon Kim; Huiyun Liang; Thomas J Slaga
Journal:  Mol Cancer Res       Date:  2013-09-26       Impact factor: 5.852

3.  Spontaneous multidrug transport in human glioma cells is regulated by transforming growth factors type beta.

Authors:  H J Schluesener; R Meyermann
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations.

Authors:  Rishil J Kathawala; Tianwen Li; Danwen Yang; Hui-Qin Guo; Dong-Hua Yang; Xiang Chen; Changmei Cheng; Zhe-Sheng Chen
Journal:  J Cell Biochem       Date:  2017-04-25       Impact factor: 4.429

5.  Functional replacement of the hemolysin A transport signal by a different primary sequence.

Authors:  F Zhang; D I Greig; V Ling
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

6.  Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.

Authors:  Megumi Murakami; Shinobu Ohnuma; Michihiro Fukuda; Eduardo E Chufan; Katsuyoshi Kudoh; Keigo Kanehara; Norihiko Sugisawa; Masaharu Ishida; Takeshi Naitoh; Hiroyuki Shibata; Yoshiharu Iwabuchi; Suresh V Ambudkar; Michiaki Unno
Journal:  Drug Metab Dispos       Date:  2017-09-13       Impact factor: 3.922

7.  Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells.

Authors:  F Kugawa; T Suzuki; M Miyata; K Tomono; F Tamanoi
Journal:  Pharmazie       Date:  2009-05       Impact factor: 1.267

8.  Effect of cyclosporine on colchicine partitioning in the rat liver.

Authors:  K V Speeg; A L Maldonado
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible.

Authors:  T D Batiuk; F Pazderka; J Enns; L DeCastro; P F Halloran
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.